1. Home
  2. SNCR vs MAIA Comparison

SNCR vs MAIA Comparison

Compare SNCR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Synchronoss Technologies Inc.

SNCR

Synchronoss Technologies Inc.

HOLD

Current Price

$8.52

Market Cap

59.5M

Sector

Technology

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.57

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNCR
MAIA
Founded
2000
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.5M
44.9M
IPO Year
2006
2022

Fundamental Metrics

Financial Performance
Metric
SNCR
MAIA
Price
$8.52
$1.57
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
292.7K
994.9K
Earning Date
11-04-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$170,909,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.07
N/A
52 Week Low
$3.98
$0.87
52 Week High
$12.85
$2.74

Technical Indicators

Market Signals
Indicator
SNCR
MAIA
Relative Strength Index (RSI) 74.48 63.82
Support Level $8.39 $1.13
Resistance Level $8.50 $1.75
Average True Range (ATR) 0.13 0.16
MACD -0.04 0.03
Stochastic Oscillator 62.79 69.35

Price Performance

Historical Comparison
SNCR
MAIA

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: